Immix Biopharma, Inc.
Immix Biopharma is a clinical-stage company developing CAR-T cell therapy NXC-201 for light chain amyloidosis and other serious diseases.
8-KNov 12Latest SEC filing
Nov 12Latest story
Immix Biopharma is a clinical-stage company developing CAR-T cell therapy NXC-201 for light chain amyloidosis and other serious diseases.